Evidence map›Paper›PMID 37496710›Full record

ReviewDiscoveries (Craiova, Romania)

Heart failure in patients with metabolic syndrome X.

Precious-Peculiar Olatunbosun, Ghalib Nashaat El Hunjul, Apurva Patel, Rabab Hunaid Abbas, Shefali Mody, Ahmad Masalha, Shivani Mehta, Shaista Rizwan, Aayushi Pareek, Suhani Jain and 1 more

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Discoveries (Craiova, Romania). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 6 countries.

Precious-Peculiar OlatunbosunUniversity of Ilorin, College of Health Sciences, Ilorin, Nigeria.
Ghalib Nashaat El HunjulDepartment of Internal Medicine, Soba University Hopsital, Khartoum, Sudan.
Apurva PatelMedical College Baroda, Vadodara, India.
Rabab Hunaid AbbasTbilisi State Medical University, Tbilisi, Georgia.
Shefali ModyLokmanya Tilak Municipal Medical College, Mumbai, India.
Ahmad MasalhaRoss University School of Medicine, Two Mile Hill, St. Michael, Barbados.
Shivani MehtaXavier University School of Medicine, Aruba.
Shaista RizwanTbilisi State Medical University, Tbilisi, Georgia.
Aayushi PareekUniversity of Perpetual Help System, Dalta, Philippines.
Suhani JainGrant Government Medical College and Sir JJ Group of Hospitals, Mumbai, India.
Silmy Bakzer Cherat ParambatTbilisi State Medical University, Tbilisi, Georgia.
Tbilisi State Medical University · GEGovernment Medical College · INLokmanya Tilak Municipal General Hospital and Lokmanya Tilak Municipal Medical College · INRoss University School of Medicine · BBSir Sayajirao General Hospital Medical College · INUniversity of Aruba · AWUniversity of Ilorin · NGUniversity of Perpetual Help System DALTA · PH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic syndrome X has been known to be a risk factor for the development of cardiovascular dysfunction. Insulin resistance, diabetes mellitus and serum lipid abnormalities, which are all seen in metabolic syndrome X, have been found to negatively impact heart function, leading to heart failure in particular. Heart failure is a condition resulting when the heart is unable to perform its function of providing sufficient blood flow to meet the body's requirements. The treatment of heart failure in metabolic syndrome X varies based on the various components of metabolic syndrome X, which include obesity, hyperglycemia, hypertension and dyslipidemia. Obesity is regarded as one of the derangements seen in patients with metabolic syndrome X. It is a significant risk factor in the development of cardiovascular disease, which may eventually lead to heart failure. However, the obesity paradox suggests that obesity provides a higher chance of survival in patients with metabolic syndrome and heart failure. This review article focuses on the pathophysiology of heart failure in patients who already have metabolic syndrome X, as well as the therapeutic management complexity of the two conditions taking into consideration the protective role provided by obesity.

Indexed as

heart failureinsulin resistanceMetabolic syndromeobesity.obesity paradox

Identifiers

PMID37496710
PMCPMC10368463
OpenAlexW4378071990

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.